News | June 17, 2008

PET Detects “Silent Heart” Stage in Asymptomatic Diabetic Patients

June 18, 2008 - Researchers using positron emission tomography (PET) are able to see changes in coronary blood vessels, offering hope that those at risk of cardiac deaths caused by disease in the heart’s vessels can receive earlier treatment and prolong life.

As many as 50 percent of all cardiac deaths due to disease in the heart’s vessels occur in individuals with no prior history or symptoms of heart disease. In addition, standard coronary risk factors may fail to explain up to 50 percent of cardiovascular events.

“Assessment of standard coronary risk factors such as arterial hypertension, smoking, hypercholesterolemia or diabetes appears to be limited in defining an individual’s future cardiac risk,” said Thomas Schindler, M.D., chief of nuclear cardiology at the University Hospitals of Geneva, Geneva, Switzerland.
Early stages of atherosclerosis (a disease affecting arterial blood vessels) can be detected by different cardiovascular imaging techniques, he explained. For example, intravascular ultrasound may identify abnormal thickening of the subintimal space (below the inner layer of blood vessels) of the carotid artery as an early sign of developing arterial disease, electron-beam or multi-detector computed tomography (MDCT) may identify calcification of the heart vessels and PET may detect functional abnormalities of the coronary arteries by unmasking mild reductions in the blood flow supply to the heart during stress testing.
Notably, the identification of abnormal thickening of the arterial wall of the carotid with intravascular ultrasound, coronary artery calcifications with MDCT and functional abnormalities of the coronary circulation with PET have all been shown to identify the initiation and development of atherosclerotic disease of the heart vessels and future cardiovascular events such as myocardial infarction, sudden cardiac death, heart failure or the need for revascularization procedures (restoring the circulatory structures) for the heart.
“These measures to detect clinically silent heart vessel disease may be more useful in defining the future cardiac risk in individuals than conventional coronary risk factor assessment and could thereby better reinforce the preventive therapy for improving the long-term cardiovascular outcome,” said Dr. Schindler.
The difficulty is, he added, that it is not known which of these markers of subclinical heart vessel disease is first to manifest.
In a study of 68 asymptomatic individuals with type 2 diabetes (or adult onset diabetes), researchers were able to determine the concurrent prevalence of the thickening in arterials walls (carotid-intima media thickness, IMT), coronary artery calcification (CAC) and functional abnormalities of the coronary circulation (coronary vascular dysfunction). In these patients—all of whom had coronary vascular dysfunction as determined by PET scans—a 56 percent increase in the prevalence of abnormal carotid IMT was found, while 66 percent also had evidence of CAC.
The results showed that when PET revealed coronary vascular dysfunction as a functional precursor of coronary artery disease, these findings were not necessarily accompanied by abnormal increases in the carotid IMT or CAC, leading researchers to believe that the dysfunction may precede structural alterations of the arterial wall.
“PET assessment of functional abnormalities of the coronary circulation, therefore, may allow the earliest identification of developing heart vessel disease. This could lead to an optimized identification of the very early stage of the development of coronary artery disease, allowing physicians to initiate and/or reinforce preventive medical therapy strategies in order to improve the long-term cardiovascular outcome in these individuals at risk for heart disease,” said Dr. Schindler.
Heart disease is one of the complications of type 2 diabetes. According to the American Heart Association, more than 80 million people in the United States have one or more forms of cardiovascular disease.

Scientific Paper 300: T. H. Schindler, V. M. Gabriella, R. Nkoulou and O. Ratib, Internal Medicine, Nuclear Cardiology and Cardiovascular Center, Geneva, Geneva, Switzerland; J. Goldin and H. R. Schelbert, Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, Calif., “Carotid Intima-media Thickness, Coronary Artery Calcification and Coronary Vasomotion in Asymoptomatic Type 2 Diabetic Patients,” SNM 55th Annual Meeting, June 14–18, 2008.

For more information: www.snm.org

Related Content

SNMMI Publishes New FDG PET/CT Appropriate Use Criteria
News | PET-CT | October 25, 2017
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has published appropriate use criteria (AUC) for FDG PET/...
Majority of Recurrent Prostate Cancer Patients' Treatment Plan Changed Following Fluciclovine 18F PET/CT
News | Prostate Cancer | October 04, 2017
Blue Earth Diagnostics recently announced the results of a pre-planned interim analysis from an investigational...
Toshiba Highlights Latest CT Advancements at RSNA 2017
News | Computed Tomography (CT) | September 18, 2017
Toshiba Medical announced that it will display several new enhancements to its existing computed tomography (CT)...
Double Targeting Ligands to Identify and Treat Prostate Cancer

The mice were imaged with small-animal PET/CT using 124I-RPS-027 (7.4 MBq [200 μCi]). Credit: JM Kelly et al., Department of Radiology, Weill Cornell Medicine, New York, NY

News | Prostate Cancer | September 14, 2017
Researchers have demonstrated a new, effective way to precisely identify and localize prostate cancer tumors while...
Blue Earth Diagnostics Announcing Results of FALCON PET/CT Trial at ASTRO 2017
News | PET-CT | September 13, 2017
September 13, 2017 — Blue Earth Diagnostics announced the upcoming oral presentation of initial results from the FALC
FDG-PET/CT Predicts Melanoma Patients' Response to Immune Checkpoint Inhibitor Therapy
News | PET-CT | September 07, 2017
September 7, 2017 — Advanced melanoma has a poor prognosis, but immune checkpoint inhibitor therapy can be effective
Videos | Nuclear Imaging | August 24, 2017
Prem Soman, M.D., director of nuclear cardiology at the Heart and Vascular Institute, University of Pittsburgh, and p
ASNC and SNMMI Release Joint Document on Diagnosis, Treatment of Cardiac Sarcoidosis
News | Cardiac Imaging | August 18, 2017
August 18, 2017 — The American Society of Nuclear Cardiology (ASNC) has released a joint expert consensus document wi
PET/CT Tracer Identifies Vulnerable Lesions in Non-Small Cell Lung Cancer Patients

Example of a patient with an upper left lung NSCLC: A: FDG; B: FDG PET/CT; C: Planning radiotherapy based on FDG (66Gy) with BTVm (GTV), CTV and PTV; D: PET FMISO E: FMISO PET/CT; F: boost based on the FMISO PET (76Gy) with BTVh (biological hypoxic target volume) and PTV boost. Credit: QuantIF – LITIS EA 4108 – FR CNRS 3638, Henri Becquerel Cancer Center, Rouen, France

News | PET-CT | July 14, 2017
July 14, 2017 — Fluorine-18 (18F)-fluoromisonidazole (FMISO) is a positron emission tomography (PET)...
Overlay Init